Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
LOS ALTOS, Calif., May 21, 2024 BUSINESS WIRE Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, Mike will be responsible for new product planning, portfolio strategy, and cross-functional leadership to maximize the impact of the Company's clinical-stage programs and biomarker platform. "Mike has dedicated his career to leading the product life cycle for companies in CNS and psychiatry, from early-stage planning and portfolio strategy through launch and brand management," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. "His expertise
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics doses first subjects in Phase I IBD treatment trial [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel Disease [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel DiseasePR Newswire
- Spyre Therapeutics Announces Grants of Inducement AwardsPR Newswire
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 5/9/24 - Miss
SYRE
Sec Filings
- 6/10/24 - Form SC
- 5/30/24 - Form 8-K
- 5/16/24 - Form 4
- SYRE's page on the SEC website